JPWO2020104676A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020104676A5 JPWO2020104676A5 JP2021529003A JP2021529003A JPWO2020104676A5 JP WO2020104676 A5 JPWO2020104676 A5 JP WO2020104676A5 JP 2021529003 A JP2021529003 A JP 2021529003A JP 2021529003 A JP2021529003 A JP 2021529003A JP WO2020104676 A5 JPWO2020104676 A5 JP WO2020104676A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- cell
- artificial
- car
- artificial feeder
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 description 55
- 210000000822 natural killer cell Anatomy 0.000 description 35
- 239000003446 ligand Substances 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 102000002698 KIR Receptors Human genes 0.000 description 8
- 108010043610 KIR Receptors Proteins 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 108010002350 Interleukin-2 Proteins 0.000 description 6
- 102000000588 Interleukin-2 Human genes 0.000 description 6
- 102000005962 receptors Human genes 0.000 description 6
- 108020003175 receptors Proteins 0.000 description 6
- 102000004127 Cytokines Human genes 0.000 description 5
- 108090000695 Cytokines Proteins 0.000 description 5
- 101001109503 Homo sapiens NKG2-C type II integral membrane protein Proteins 0.000 description 5
- 101001136592 Homo sapiens Prostate stem cell antigen Proteins 0.000 description 5
- 108091008877 NK cell receptors Proteins 0.000 description 5
- 102100022683 NKG2-C type II integral membrane protein Human genes 0.000 description 5
- 102100021462 Natural killer cells antigen CD94 Human genes 0.000 description 5
- 102100036735 Prostate stem cell antigen Human genes 0.000 description 5
- 239000000427 antigen Substances 0.000 description 5
- 102000036639 antigens Human genes 0.000 description 5
- 108091007433 antigens Proteins 0.000 description 5
- -1 e.g. Proteins 0.000 description 5
- 239000013604 expression vector Substances 0.000 description 5
- 239000012528 membrane Substances 0.000 description 5
- 102100028970 HLA class I histocompatibility antigen, alpha chain E Human genes 0.000 description 4
- 101000986085 Homo sapiens HLA class I histocompatibility antigen, alpha chain E Proteins 0.000 description 4
- 102100029740 Poliovirus receptor Human genes 0.000 description 4
- 230000004913 activation Effects 0.000 description 4
- 108010087914 epidermal growth factor receptor VIII Proteins 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 102000039446 nucleic acids Human genes 0.000 description 4
- 108020004707 nucleic acids Proteins 0.000 description 4
- 150000007523 nucleic acids Chemical class 0.000 description 4
- 230000001681 protective effect Effects 0.000 description 4
- 230000011664 signaling Effects 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 241000700605 Viruses Species 0.000 description 3
- 230000003213 activating effect Effects 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 230000003013 cytotoxicity Effects 0.000 description 3
- 231100000135 cytotoxicity Toxicity 0.000 description 3
- 102000055277 human IL2 Human genes 0.000 description 3
- 239000008194 pharmaceutical composition Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 108010082808 4-1BB Ligand Proteins 0.000 description 2
- 102100032529 C-type lectin domain family 1 member B Human genes 0.000 description 2
- 102100026193 C-type lectin domain family 2 member A Human genes 0.000 description 2
- 102100026194 C-type lectin domain family 2 member B Human genes 0.000 description 2
- 102100026197 C-type lectin domain family 2 member D Human genes 0.000 description 2
- 102000002086 C-type lectin-like Human genes 0.000 description 2
- 108050009406 C-type lectin-like Proteins 0.000 description 2
- 102100036008 CD48 antigen Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 101000942284 Homo sapiens C-type lectin domain family 1 member B Proteins 0.000 description 2
- 101000912608 Homo sapiens C-type lectin domain family 2 member A Proteins 0.000 description 2
- 101000912618 Homo sapiens C-type lectin domain family 2 member B Proteins 0.000 description 2
- 101000912615 Homo sapiens C-type lectin domain family 2 member D Proteins 0.000 description 2
- 101000716130 Homo sapiens CD48 antigen Proteins 0.000 description 2
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 2
- 101000991060 Homo sapiens MHC class I polypeptide-related sequence A Proteins 0.000 description 2
- 101000586618 Homo sapiens Poliovirus receptor Proteins 0.000 description 2
- 101000831007 Homo sapiens T-cell immunoreceptor with Ig and ITIM domains Proteins 0.000 description 2
- 241000701024 Human betaherpesvirus 5 Species 0.000 description 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 description 2
- 102100030301 MHC class I polypeptide-related sequence A Human genes 0.000 description 2
- 108010001880 NK Cell Lectin-Like Receptor Subfamily C Proteins 0.000 description 2
- 102000000834 NK Cell Lectin-Like Receptor Subfamily C Human genes 0.000 description 2
- 101150030723 RIR2 gene Proteins 0.000 description 2
- 102100024834 T-cell immunoreceptor with Ig and ITIM domains Human genes 0.000 description 2
- 102100032101 Tumor necrosis factor ligand superfamily member 9 Human genes 0.000 description 2
- 102100022153 Tumor necrosis factor receptor superfamily member 4 Human genes 0.000 description 2
- 101150100826 UL40 gene Proteins 0.000 description 2
- 108010093857 Viral Hemagglutinins Proteins 0.000 description 2
- 229940034982 antineoplastic agent Drugs 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 108010048507 poliovirus receptor Proteins 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 229960004641 rituximab Drugs 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 230000003827 upregulation Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 102400000069 Activation peptide Human genes 0.000 description 1
- 101800001401 Activation peptide Proteins 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- 102000006306 Antigen Receptors Human genes 0.000 description 1
- 102100028967 HLA class I histocompatibility antigen, alpha chain G Human genes 0.000 description 1
- 108010024164 HLA-G Antigens Proteins 0.000 description 1
- 102100029360 Hematopoietic cell signal transducer Human genes 0.000 description 1
- 101000990188 Homo sapiens Hematopoietic cell signal transducer Proteins 0.000 description 1
- 101001109508 Homo sapiens NKG2-A/NKG2-B type II integral membrane protein Proteins 0.000 description 1
- 101000971513 Homo sapiens Natural killer cells antigen CD94 Proteins 0.000 description 1
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 101000809875 Homo sapiens TYRO protein tyrosine kinase-binding protein Proteins 0.000 description 1
- 102000037982 Immune checkpoint proteins Human genes 0.000 description 1
- 108091008036 Immune checkpoint proteins Proteins 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000005551 L01XE03 - Erlotinib Substances 0.000 description 1
- 101710135898 Myc proto-oncogene protein Proteins 0.000 description 1
- 102100038895 Myc proto-oncogene protein Human genes 0.000 description 1
- 102100022682 NKG2-A/NKG2-B type II integral membrane protein Human genes 0.000 description 1
- 102000010648 Natural Killer Cell Receptors Human genes 0.000 description 1
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102100038717 TYRO protein tyrosine kinase-binding protein Human genes 0.000 description 1
- 101710150448 Transcriptional regulator Myc Proteins 0.000 description 1
- 101710165473 Tumor necrosis factor receptor superfamily member 4 Proteins 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229960001686 afatinib Drugs 0.000 description 1
- ULXXDDBFHOBEHA-CWDCEQMOSA-N afatinib Chemical compound N1=CN=C2C=C(O[C@@H]3COCC3)C(NC(=O)/C=C/CN(C)C)=CC2=C1NC1=CC=C(F)C(Cl)=C1 ULXXDDBFHOBEHA-CWDCEQMOSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 1
- 229960003852 atezolizumab Drugs 0.000 description 1
- 229950002916 avelumab Drugs 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 229960005395 cetuximab Drugs 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 229950009791 durvalumab Drugs 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 1
- 229960001433 erlotinib Drugs 0.000 description 1
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000000684 flow cytometry Methods 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 229960002584 gefitinib Drugs 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229940126546 immune checkpoint molecule Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 1
- 229960003301 nivolumab Drugs 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 229960003278 osimertinib Drugs 0.000 description 1
- DUYJMQONPNNFPI-UHFFFAOYSA-N osimertinib Chemical compound COC1=CC(N(C)CCN(C)C)=C(NC(=O)C=C)C=C1NC1=NC=CC(C=2C3=CC=CC=C3N(C)C=2)=N1 DUYJMQONPNNFPI-UHFFFAOYSA-N 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229960000575 trastuzumab Drugs 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 150000004917 tyrosine kinase inhibitor derivatives Chemical group 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18208092.9A EP3656851A1 (en) | 2018-11-23 | 2018-11-23 | Artificial hla-positive feeder cell lines for nk cells and uses thereof |
| EP18208092.9 | 2018-11-23 | ||
| PCT/EP2019/082283 WO2020104676A1 (en) | 2018-11-23 | 2019-11-22 | Artificial hla-positive feeder cell lines for nk cells and uses thereof |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022513116A JP2022513116A (ja) | 2022-02-07 |
| JPWO2020104676A5 true JPWO2020104676A5 (enrdf_load_stackoverflow) | 2022-09-30 |
| JP7450892B2 JP7450892B2 (ja) | 2024-03-18 |
Family
ID=64664021
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021529003A Active JP7450892B2 (ja) | 2018-11-23 | 2019-11-22 | Ｎｋ細胞のための人工ｈｌａ陽性フィーダー細胞株及びその使用 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US11578307B2 (enrdf_load_stackoverflow) |
| EP (2) | EP3656851A1 (enrdf_load_stackoverflow) |
| JP (1) | JP7450892B2 (enrdf_load_stackoverflow) |
| CA (1) | CA3119403C (enrdf_load_stackoverflow) |
| WO (1) | WO2020104676A1 (enrdf_load_stackoverflow) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7118055B2 (ja) * | 2016-09-29 | 2022-08-15 | イプセン バイオファーム リミテッド | ハイブリッド神経毒 |
| CA3089853A1 (en) | 2018-02-01 | 2019-08-08 | Nkmax Co., Ltd. | Method of producing natural killer cells and composition for treating cancer |
| CN115052973B (zh) * | 2019-11-06 | 2025-07-01 | 贝勒医学院 | 用于产生细胞毒性效应子记忆t细胞以用于癌症的t细胞治疗的方法 |
| EP4163366A4 (en) * | 2020-06-09 | 2024-08-21 | Samsung Life Public Welfare Foundation | GENETICALLY MODIFIED CELL LINE FOR ACTIVATION AND AMPLIFICATION OF NK CELLS AND USE THEREOF |
| CN112048482A (zh) * | 2020-09-09 | 2020-12-08 | 广东昭泰体内生物医药科技有限公司 | 一种nk样细胞的培养方法 |
| US12264184B2 (en) * | 2021-02-23 | 2025-04-01 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | DAP12 constructs and their use to enhance DC vaccines and immunotherapies |
| TW202338085A (zh) * | 2021-11-18 | 2023-10-01 | 美商健生生物科技公司 | 用於擴增自然殺手細胞製劑之無餵養細胞培養方法 |
| WO2023096352A1 (ko) * | 2021-11-25 | 2023-06-01 | 사회복지법인 삼성생명공익재단 | Hla-e를 발현하도록 유전적으로 조작된 배양보조세포주, 및 그의 용도 |
| CN117343906A (zh) * | 2022-07-04 | 2024-01-05 | 上海优卡迪生物医药科技有限公司 | 表达重组抗原蛋白的饲养细胞及其制备方法和应用 |
| CN115725509B (zh) * | 2022-12-09 | 2025-07-04 | 上海贝斯昂科生物科技有限公司 | 一种基因工程细胞的制备及其在nk细胞体外扩增中的应用 |
| KR102669705B1 (ko) * | 2023-02-24 | 2024-06-10 | 이엔셀 주식회사 | 제대혈 유래 자연 살해 세포의 확장배양방법 |
| CN116286666B (zh) * | 2023-05-15 | 2023-08-04 | 成都云测医学生物技术有限公司 | 滋养层细胞及其制备方法、应用和扩增nk细胞的方法 |
| WO2025067151A1 (en) * | 2023-09-25 | 2025-04-03 | Nanjing Legend Biotech Co., Ltd. | Modified immune cells and calcineurin inhibitors and uses thereof |
| GB202317912D0 (en) * | 2023-11-23 | 2024-01-10 | Univ College Cardiff Consultants Ltd | Viral-based immuno therapeutic |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4353888A (en) | 1980-12-23 | 1982-10-12 | Sefton Michael V | Encapsulation of live animal cells |
| US4744933A (en) | 1984-02-15 | 1988-05-17 | Massachusetts Institute Of Technology | Process for encapsulation and encapsulated active material system |
| US4749620A (en) | 1984-02-15 | 1988-06-07 | Massachusetts Institute Of Technology | Encapsulated active material system |
| JPH0628570B2 (ja) | 1986-02-13 | 1994-04-20 | 雪印乳業株式会社 | カプセル体の製造方法及び装置 |
| EP0301777A1 (en) | 1987-07-28 | 1989-02-01 | Queen's University At Kingston | Multiple membrane microencapsulation |
| US5089272A (en) | 1989-03-29 | 1992-02-18 | Snow Brand Milk Products Co., Ltd. | Process for producing capsules having a permeability-controllable membrane |
| US5084350A (en) | 1990-02-16 | 1992-01-28 | The Royal Institution For The Advance Of Learning (Mcgill University) | Method for encapsulating biologically active material including cells |
| US5578442A (en) | 1992-03-23 | 1996-11-26 | Vivorx, Inc. | Graft copolymers of polycationic species and water-soluble polymers, and use therefor |
| JP4098355B2 (ja) | 1993-08-12 | 2008-06-11 | ニューロテック ユーエスエー， インコーポレイテッド | 遺伝的に改変された細胞を含む生体適合性免疫隔離カプセル |
| CA2831018A1 (en) * | 2011-03-25 | 2012-10-04 | Txcell | Method for using regulatory t cells in therapy |
| EP2702145A1 (en) * | 2011-04-28 | 2014-03-05 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for preparing accessory cells and uses thereof for preparing activated nk cells |
| ES2871349T3 (es) * | 2012-09-04 | 2021-10-28 | Inven2 As | Expansión selectiva y controlada de células NK educadas |
| WO2015010096A1 (en) * | 2013-07-18 | 2015-01-22 | Baylor College Of Medicine | Method of enhancing potency of immune cells |
| JP7049830B2 (ja) * | 2014-10-27 | 2022-04-07 | ユニバーシティ オブ セントラル フロリダ リサーチ ファウンデーション，インコーポレイテッド | ナチュラルキラー細胞のための方法及び組成物 |
| GB201616237D0 (en) * | 2016-09-23 | 2016-11-09 | Univ Oslo Hf | Modulation of function of immune effector cells |
-
2018
- 2018-11-23 EP EP18208092.9A patent/EP3656851A1/en not_active Withdrawn
-
2019
- 2019-11-22 WO PCT/EP2019/082283 patent/WO2020104676A1/en unknown
- 2019-11-22 US US17/293,895 patent/US11578307B2/en active Active
- 2019-11-22 JP JP2021529003A patent/JP7450892B2/ja active Active
- 2019-11-22 CA CA3119403A patent/CA3119403C/en active Active
- 2019-11-22 EP EP19806246.5A patent/EP3884040A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220296690A1 (en) | Engineered t cells and uses therefor | |
| US20250090542A1 (en) | Combination of a cell therapy and a gamma secretase inhibitor | |
| JP2024038039A (ja) | キメラ活性化受容体及びキメラ刺激受容体を発現する細胞並びにその使用 | |
| Hornig et al. | Combination of a bispecific antibody and costimulatory antibody-ligand fusion proteins for targeted cancer immunotherapy | |
| US20220348631A1 (en) | Receptors providing targeted costimulation for adoptive cell therapy | |
| US20230190796A1 (en) | Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods | |
| JP2022518240A (ja) | 養子細胞療法のための標的共刺激を提供する受容体 | |
| CN109651511B (zh) | 一种靶向bcma的嵌合抗原受体及其应用 | |
| CA3032054A1 (en) | Combination therapies of chimeric antigen receptors and pd-1 inhibitors | |
| JP2024023228A5 (enrdf_load_stackoverflow) | ||
| KR20230007559A (ko) | 태그된 키메라 이펙터 분자 및 그의 리셉터 | |
| JPWO2020104676A5 (enrdf_load_stackoverflow) | ||
| CN110035768A (zh) | 嵌合抗原受体 | |
| US10023648B2 (en) | Anti-TOSO chimeric antigen receptor and its use | |
| CN113795262A (zh) | 人源化抗dll3嵌合抗原受体及其用途 | |
| BR112021007995A2 (pt) | molécula de anticorpo antagonista, sequência de nucleotídeos isolada, plasmídeo, vírus, célula, uso de uma molécula de anticorpo, composição farmacêutica, método para tratar câncer ou uma infecção causada por um patógeno intracelular em um paciente | |
| US20250145683A1 (en) | Engineered immune cells with dominant signals | |
| JPWO2021071962A5 (enrdf_load_stackoverflow) | ||
| JP2023541132A (ja) | 免疫細胞におけるアダプターの誘導性発現のための系 | |
| Cantoni et al. | Inhibitory and Activating Natural Killer Receptors in Humans: A Historical Overview | |
| Battin et al. | Engineered soluble, trimerized 4-1BBL variants as potent immunomodulatory agents | |
| US20250121007A1 (en) | Compositions for the treatment of cancer | |
| KR20250089551A (ko) | 입양 세포 요법과 표적 면역사이토카인을 조합하여 이용한 암 치료 방법 | |
| HK40041676A (en) | Anti-mesothelin chimeric antigen receptor (car) constructs and uses thereof | |
| WO2024240112A1 (zh) | 免疫效应细胞及其应用 |